PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PriMOVANE®
Zopiclone
Tablets, 5.0 mg and 7.5 mg, Oral Administration
Hypnotic and Sedative

sanofi-aventis Canada Inc.
1755 Steeles Avenue West
Toronto ON,
M2R 3T4

Date of Initial Authorization:
August 02, 1990
Date of Revision:
April 6, 2022
Submission Control Number: 258560
Table of Contents

RECENT MAJOR LABEL CHANGES .................................................................................................................. 2
TABLE OF CONTENTS ......................................................................................................................................... 2
PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................................... 4
1  INDICATIONS .................................................................................................................................................. 4
   1.1  Pediatrics (< 18 years of age) ................................................................................................................... 4
   1.2  Geriatrics (≥ 65 years of age) .................................................................................................................. 4
2  CONTRAINDICATIONS .................................................................................................................................... 4
3  SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................................... 5
4  DOSAGE AND ADMINISTRATION .................................................................................................................... 6
   4.1  Dosing Considerations ............................................................................................................................... 6
   4.2  Recommended Dose and Dosage Adjustment ............................................................................................. 6
   4.4  Administration ........................................................................................................................................... 7
   4.5  Missed Dose .............................................................................................................................................. 7
5  OVERDOSAGE .................................................................................................................................................. 7
6  DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .......................................................... 8
7  WARNINGS AND PRECAUTIONS .................................................................................................................... 9
   7.1  Special Populations ................................................................................................................................... 14
   7.1.1  Pregnant Women ..................................................................................................................................... 14
   7.1.2  Breast-feeding ....................................................................................................................................... 15
   7.1.3  Pediatrics (< 18 years of age): ................................................................................................................. 15
   7.1.4  Geriatrics (≥ 65 years of age): ................................................................................................................. 15
8  ADVERSE REACTIONS ................................................................................................................................. 15
   8.1  Adverse Reaction Overview ....................................................................................................................... 15
8.2 Clinical Trial Adverse Reactions .............................................................. 15
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ................................................................. 17
8.5 Post-Market Adverse Reactions ................................................................. 17

9 DRUG INTERACTIONS .............................................................................. 18
  9.1 Serious Drug Interactions ...................................................................... 18
  9.2 Drug Interactions Overview .................................................................. 18
  9.3 Drug-Behavioural Interactions .............................................................. 18
  9.4 Drug-Drug Interactions ...................................................................... 18
  9.5 Drug-Food Interactions ...................................................................... 19
  9.6 Drug-Herb Interactions ...................................................................... 19
  9.7 Drug-Laboratory Test Interactions ....................................................... 19

10 CLINICAL PHARMACOLOGY .................................................................. 19
  10.1 Mechanism of Action ....................................................................... 19
  10.2 Pharmacodynamics ......................................................................... 21
  10.3 Pharmacokinetics ........................................................................... 22

11 STORAGE, STABILITY AND DISPOSAL ............................................... 23

12 SPECIAL HANDLING INSTRUCTIONS .................................................. 23

PART II: SCIENTIFIC INFORMATION ....................................................... 24

13 PHARMACEUTICAL INFORMATION ...................................................... 24

14 CLINICAL TRIALS ................................................................................ 25

15 MICROBIOLOGY .................................................................................. 25

16 NON-CLINICAL TOXICOLOGY .............................................................. 25

PATIENT MEDICATION INFORMATION ............................................... 31
PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

IMOVANE (zopiclone) is indicated for short-term (usually not exceeding 7-10 days) use for:

- treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep
- frequent nocturnal awakenings and/or early morning awakenings

where disturbed sleep results in impaired daytime functioning (see 4.4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations).

1.1 Pediatrics (< 18 years of age)

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics (≥ 65 years of age)

Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 4 DOSAGE AND ADMINISTRATION, 7.1.4 Geriatrics patients (≥ 65 years of age)).

Long-term use of IMOVANE should be avoided, including in geriatric patients. Enhanced monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and Fractures; 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations).

2 CONTRAINDICATIONS

IMOVAE is contraindicated in patients:

- With known hypersensitivity to the drug or to any component in its formulation. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
- With myasthenia gravis
- With severe hepatic insufficiency
- With severe impairment of respiratory function (e.g., significant sleep apnea syndrome).
- Who have previously experienced complex sleep behaviours after taking any non-benzodiazepine sedative-hypnotic.
SERIOUS WARNINGS AND PRECAUTIONS BOX

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Addiction, Abuse and Misuse</strong></td>
</tr>
<tr>
<td>The use of benzodiazepines, or other sedative-hypnotic drugs, such as IMOVANE, can lead to abuse, misuse, addiction, physical dependence and withdrawal reactions. Abuse and misuse can result in overdose or death, especially when benzodiazepines, or other sedative-hypnotic drugs, such as IMOVANE, are combined with other medicines, such as opioids, alcohol or illicit drugs.</td>
</tr>
<tr>
<td>• Assess each patient’s risk prior to prescribing IMOVANE</td>
</tr>
<tr>
<td>• Monitor all patients regularly for the development of these behaviours or conditions.</td>
</tr>
<tr>
<td>• IMOVANE should be stored securely to avoid theft or misuse.</td>
</tr>
<tr>
<td><strong>Withdrawal</strong></td>
</tr>
<tr>
<td>Benzodiazepines, or other sedative-hypnotic drugs, such as IMOVANE, can produce severe or life-threatening withdrawal symptoms.</td>
</tr>
<tr>
<td>• Avoid abrupt discontinuation or rapid dose reduction of IMOVANE.</td>
</tr>
<tr>
<td>• Terminate treatment with IMOVANE by gradually tapering the dosage schedule under close monitoring. (see 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance)</td>
</tr>
<tr>
<td><strong>Risks from Concomitant Use with Opioids</strong></td>
</tr>
<tr>
<td>Concomitant use of IMOVANE and opioids may result in profound sedation, respiratory depression, coma and death (see 7 WARNINGS AND PRECAUTIONS, General, Concomitant Use with Opioids).</td>
</tr>
<tr>
<td>• Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are not possible.</td>
</tr>
<tr>
<td>• Limit dosages and durations to the minimum required.</td>
</tr>
<tr>
<td>• Follow patients for signs and symptoms of respiratory depression and sedation.</td>
</tr>
<tr>
<td><strong>Complex sleep behaviours</strong></td>
</tr>
<tr>
<td>• Complex sleep behaviours including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of non-benzodiazepine sedative-hypnotics. Some of these events may result in serious injuries, including death. Discontinue IMOVANE immediately if a patient experiences a complex sleep behavior. (See 7 WARNINGS AND PRECAUTIONS, Complex Sleep Behaviours)</td>
</tr>
</tbody>
</table>
4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder. Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated.

- The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning.

- Treatment with IMOVANE should usually not exceed 7-10 consecutive days. Use for more than 2-3 consecutive weeks requires complete re-evaluation of the patient. Prescriptions for IMOVANE should be written for short-term use (7-10 days) and it should not be prescribed in quantities exceeding a 1-month supply.

- IMOVANE should always be prescribed at the lowest effective dose for the shortest duration possible.

- IMOVANE can produce withdrawal signs and symptoms or rebound phenomena following abrupt discontinuation or rapid dose reduction (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Withdrawal; 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance). Abrupt discontinuation should be avoided and treatment - even if only of short duration - should be terminated by gradually tapering the dosage schedule under close monitoring.

- Tapering should be tailored to the specific patient. Special attention should be given to patients with a history of seizure (see 7 WARNINGS AND PRECAUTIONS).

- If a patient experiences withdrawal signs and symptoms, consider postponing the taper or raising the IMOVANE dose, to the previous dosage prior to proceeding with a gradual taper.

- Geriatric patients in particular may be more sensitive to IMOVANE (see 7 WARNINGS AND PRECAUTIONS, Falls and Fractures).

- Long-term use of IMOVANE should be avoided, including in geriatric patients. Enhanced monitoring is recommended.

- Lactose is a non-medicinal ingredient in IMOVANE 5 mg. Patients with rare hereditary diseases of galactose intolerance (galactosemia or glucose-galactose malabsorption) should not take IMOVANE 5 mg. IMOVANE 7.5 mg does not contain lactose (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).

4.2 Recommended Dose and Dosage Adjustment

Use the lowest effective dose of IMOVANE for the patient. IMOVANE should be taken in a single intake and not be re-administered during the same night.

The product should be taken just before retiring for the night.

**Adult dose:** The recommended initial dose is 3.75 mg (one-half of a 7.5 mg tablet). The dose can be increased to 5 mg and further to 7.5 mg if clinically indicated. In some patients, the higher doses result in zopiclone blood levels in the morning high enough to produce impairment of driving and other activities that require full alertness (see 7 WARNINGS AND PRECAUTIONS, CNS Depressant Effects and...
Next-Day Impairment).

The 7.5 mg dose should not be exceeded (see 7 WARNINGS AND PRECAUTIONS).

**Geriatrics (≥ 65 years of age):** In the elderly and/or debilitated patient an initial dose of 3.75 mg (one-half of a 7.5 mg tablet) at bedtime is recommended. The dose may be increased to a maximum of 5 mg if the starting dose does not offer adequate therapeutic effect.

**Patients with impaired liver function:** The recommended dose is 3.75 mg (one-half of a 7.5 mg tablet) depending on acceptability and efficacy. If clinically indicated, a 5 mg may be used with caution in appropriate cases.

**IMOVANE is contraindicated in patients with severe hepatic insufficiency** (see 2 CONTRAINDICATIONS).

**Patients with renal insufficiency:** Although no accumulation of IMOVANE or of its metabolites has been detected in cases of renal insufficiency, it is recommended that patients with impaired renal function should start treatment with 3.75 mg (one-half of a 7.5 mg tablet). If clinically indicated, a 5 mg may be used with caution in appropriate cases.

**Patients with chronic respiratory insufficiency:** The recommended dose is 3.75 mg (one-half of a 7.5 mg tablet) depending on acceptability and efficacy. Up to 7.5 mg may be used with caution in appropriate cases.

**IMOVANE is contraindicated in patients with severe impairment of respiratory function,** e.g., significant sleep apnea syndrome (see 2 CONTRAINDICATIONS).

**Use with potent CYP3A4 inhibitors:** An initial dose of 3.75 mg (one-half of a 7.5 mg tablet) at bedtime is recommended (see 9 DRUG INTERACTIONS). If clinically indicated, 5 mg may be used with caution in appropriate cases.

**Use with CNS depressants:** Dosage adjustment may be necessary when IMOVANE is combined with other CNS-depressants because of the potentially additive effects (see 9 DRUG INTERACTIONS).

**Pediatrics (< 18 years of age):** IMOVANE is not indicated for patients under 18 years of age.

### 4.4 Administration

Tablets are for oral administration. The 7.5 mg tablet can be broken into two equal parts of 3.75 mg.

### 4.5 Missed Dose

Patients should be instructed to take IMOVANE at bedtime just before retiring for the night. Patients who miss a dose should wait to take the next dose at the regular time. The missed dose must be skipped to avoid taking a double dose.

### 5 OVERDOSAGE

**Signs and Symptoms:** Overdose is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma according to the quantity ingested. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more severe cases, symptoms may include ataxia, hypotonia, hypotension, methaemoglobinemia, respiratory depression, and coma. Overdose should not be life threatening unless combined with other CNS depressants, including alcohol. Other risk factors, such as the presence of concomitant illness and the debilitated state of the patient, may contribute to the severity of symptoms and very rarely can result in fatal outcome.
In voluntary or accidental cases of IMOVANE overdosage involving doses up to 340 mg, the principal effects reported were prolonged sleep, drowsiness, lethargy and ataxia.

**Recommended Treatment:** Symptomatic and supportive treatment in adequate clinical environment is recommended, attention should be paid to respiratory and cardiovascular functions. Activated charcoal is only useful when performed soon after ingestion.

Hemodialysis is of no value due to the large volume of distribution of IMOVANE. Flumazenil may be a useful antidote; however, flumazenil administration may contribute to the appearance of neurological symptoms (agitation, anxiety, convulsions and emotional lability). Intravenous fluids should be administered as needed.

As with the management of all overdosage, the possibility of multiple drug ingestion should be considered.

For management of a suspected drug overdose, contact your regional poison control centre.

### 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

#### Table – Dosage Forms, Strengths, Composition and Packaging

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength/Composition</th>
<th>Non-medicinal Ingredients</th>
</tr>
</thead>
</table>
| Oral                    | Tablet 7.5 mg                     | Core: croscarmellose sodium, calcium phosphate dihydrate dibasic, magnesium stearate, microcrystalline cellulose.  
Coating: carnauba wax, FD&C Blue #1, Opadry II White, polyethylene glycol. |
| Oral                    | Tablet 5.0 mg                     | Core: corn starch, dicalcium phosphate, lactose, magnesium stearate, sodium carboxymethyl starch.  
Coating: hydroxypropyl-methylcellulose, titanium dioxide |

**Zopiclone 7.5 mg:**

Each oval, scored, blue tablet, marked IMOVANE on one side and the logo rPr on each side of the score on the other side, contains zopiclone 7.5 mg. The 7.5 mg tablet can be broken into two equal parts of 3.75 mg.

Available in white high-density polyethylene bottles of 100 and 500.

**Zopiclone 5.0 mg:**

Each round, white tablet, marked IMOVANE 5 on one side and the logo rPr on the other, contains zopiclone 5.0 mg.
Available in white high-density polyethylene bottles of 100.

7 WARNINGS AND PRECAUTIONS

General

The cause of insomnia should be identified wherever possible and the underlying factors treated before a hypnotic is prescribed. The failure of insomnia to remit after 7-10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness or the presence of sleep state misperception.

Worsening of insomnia or the emergence of new abnormalities of thinking or behaviour may be the consequence of an unrecognized psychiatric or physical disorder. These have also been reported to occur in association with the use of drugs that act at the benzodiazepine receptors.

IMOVANE should be used with caution in patients who in the past manifested paradoxical reactions to alcohol and/or sedative medications.

Concomitant Use with Opioids: Concomitant use of IMOVANE and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are not possible (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Risks from Concomitant Use with Opioids; 9 DRUG INTERACTIONS, Serious Drug Interactions).

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs, such as IMOVANE, with opioids.

If a decision is made to prescribe IMOVANE concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of IMOVANE than indicated, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking IMOVANE, prescribe a lower initial dose of the opioid analgesic and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation (see 5 OVERDOSAGE).

Advise both patients and caregivers about the risks of respiratory depression and sedation when IMOVANE is used with opioids.

Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the opioid have been determined (see 7 WARNINGS AND PRECAUTIONS, Driving and Operating Machinery).

Complex Sleep Behaviours

Complex sleep behaviours, including sleep-walking, sleep-driving and engaging in other activities while not fully awake, have been reported in patients who have taken IMOVANE. These behaviours may occur following the first or any subsequent use of IMOVANE. Patients can be seriously injured or injure others during complex sleep behaviours. Such injuries may be fatal. Other complex sleep behaviours (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Postmarketing reports have shown that complex sleep behaviours may occur with IMOVANE at recommended doses, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants (see 9 DRUG INTERACTIONS). Discontinue
IMOVANE immediately if a patient experiences a complex sleep behaviour (see 2 
CONTRAINDICATIONS).

IMOVANE is not to be taken with alcohol

Caution is needed with concomitant use of other CNS depressants drugs as this appears to increase the risk of complex sleep behaviours.

Caution is recommended in patients with a personal or family history of sleepwalking. Although complex sleep behaviours have been reported in patients with or without history of sleepwalking, it is possible that some predisposed patients are at increased risk of experiencing these complex behaviours during treatment with IMOVANE.

The use of IMOVANE in patients with other disorders known to affect sleep and induce frequent awakenings (e.g. sleep apnea, Periodic Limb Movement Disorder, Restless Legs Syndrome) is discouraged, as they may be also at increased risk of complex sleep behaviours.

Treatment with IMOVANE is limited to a short duration (see 1 INDICATIONS, 4 DOSAGE AND ADMINISTRATION).

Patients should be instructed not to exceed the maximum recommended dose as this appears to increase the risk of complex sleep behaviours.

Caution should be exercised with concomitant use of potent CYP3A4 inhibitors (see 9 DRUG INTERACTIONS).

Due to the risk to the patient and the community, discontinuation of IMOVANE should be strongly considered for patients who report any such complex sleep behaviours.

Dependence/Tolerance

Use of benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, can lead to abuse, misuse, addiction, physical dependence (including tolerance) and withdrawal reactions. Abuse and misuse can result in overdose or death, especially when benzodiazepines, or other sedative-hypnotic drugs, such as IMOVANE, are combined with other medicines, such as opioids, alcohol, or illicit drugs.

The risk of dependence increases with higher doses and longer term use but can occur with short-term use at recommended therapeutic doses. Cases of dependence have been reported more frequently in patients treated with IMOVANE for longer than 4 weeks. The risk of dependence is greater in patients with a history of psychiatric disorders and/or substance (including alcohol) use disorder. Interdose daytime anxiety and rebound anxiety may increase the risk of dependency in IMOVANE treated patients

- Discuss the risks of treatment with IMOVANE with the patient, considering alternative (including non-drug) treatment options.
- Carefully evaluate each patient’s risk of abuse, misuse and addiction, considering their medical condition and concomitant drug use, prior to prescribing IMOVANE. In individuals prone to substance use disorder, IMOVANE should only be administered if deemed medically necessary, employing extreme caution and close supervision.
- IMOVANE should always be prescribed at the lowest effective dose for the shortest duration possible.
- All patients receiving benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, should be routinely monitored for signs and symptoms of misuse and abuse. If a substance use disorder is
suspected, evaluate the patient and refer them for substance abuse treatment, as appropriate.

Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms.

**Withdrawal:** Benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, can produce withdrawal signs and symptoms, ranging from mild to severe and even life threatening, following abrupt discontinuation or rapid dose reduction. The risk of withdrawal is higher with higher dosages and/or prolonged use, but can occur with short-term use at recommended therapeutic doses. Patients given therapeutic dosages for as few as 1-2 weeks can also have withdrawal symptoms including daytime anxiety between nightly doses.

Since symptoms of withdrawal are often similar to those for which the patient is being treated, it may be difficult to distinguish from a relapse of the patient’s condition.

Severe or life-threatening signs and symptoms of withdrawal include delirium, derealisation, depersonalisation, hallucinations, hyperacusis, seizures (including status epilepticus). (See 8.2 Clinical Trial Adverse Reactions, Withdrawal Symptoms).

Other withdrawal signs and symptoms, similar in character to those noted with barbiturates and alcohol, include abdominal and muscle cramps, cognitive impairment, convulsions, diarrhea, dysphoria, extreme anxiety, headache, hypersensitivity to light, noise and physical contact, insomnia, irritability, muscle pain or stiffness, paresthesia, perceptual disturbances, restlessness, sweating, tension, tremors and vomiting. There is also a possibility of rebound anxiety or rebound insomnia.

- Abrupt discontinuation should be avoided and treatment - even if only of short duration - should be terminated by gradually tapering the dosage schedule under close monitoring.
- Tapering should be tailored to the specific patient. Special attention should be given to patients with a history of seizure.
- If a patient experiences withdrawal symptoms, consider postponing the taper or raising the IMOVANE dose to the previous dosage prior to proceeding with a gradual taper.
- Inform patients of risk of discontinuing abruptly, reducing dosage rapidly or switching medications.
- As with all hypnotics, repeat prescriptions should be limited to those who are under medical supervision.
- Stress the importance of consulting with their health care professional in order to discontinue safely.
- It may be useful to inform the patient when treatment is started that it will be of limited duration and to explain precisely how the dosage will be progressively decreased.
- Patients experiencing withdrawal symptoms should seek immediate medical attention.

(see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Addiction, Abuse and Misuse, Withdrawal; 4 DOSAGE AND ADMINISTRATION, Dosing Considerations)

**Rebound insomnia:** A transient syndrome, whereby the symptoms that led to treatment with a sedative/hypnotic agent may recur in an enhanced form, upon treatment withdrawal. It may be accompanied by other reactions, including mood changes, anxiety and restlessness.

Since the risk of such phenomena is greater after abrupt discontinuation of IMOVANE, especially after prolonged treatment, it is, therefore recommended to decrease the dosage gradually and to advise the patient accordingly (see 8 ADVERSE REACTIONS). It is important that the patient should be aware of the possibility of rebound phenomena, thereby minimizing anxiety over such symptoms should they occur while the medicinal product is being discontinued.
Driving and Operating Machinery

**CNS Depressant Effects and Next-Day Impairment:** Like other sedative/hypnotic drugs, IMOVANE has CNS-depressant effects. Due to the rapid onset of action, IMOVANE should be ingested immediately prior to going to bed.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug.

This includes potential impairment of the performance of such activities that may occur the day following ingestion of IMOVANE. The risk of next day psychomotor impairment, including impaired driving, is increased if IMOVANE is taken with less than a full night of sleep remaining; if a higher dose than the recommended dose is taken; if co-administered with other CNS depressants or drugs that increase the blood level of zopiclone. Patients should be cautioned against taking IMOVANE in these circumstances.

IMOVANE is not to be taken with alcohol or other sedative hypnotics (including other zopiclone products) at bedtime or the middle of the night. If concomitant use of another CNS depressant or a drug that increases zopiclone blood levels is clinically warranted, dosage adjustments of IMOVANE may be necessary.

Even if IMOVANE is taken as instructed, some patients may still have zopiclone blood levels in the morning high enough to produce impairment (see 4 DOSAGE AND ADMINISTRATION and 9 DRUG INTERACTIONS).

**Patient counseling information regarding next-day impairment:** Tell patients that IMOVANE has the potential to cause next-day impairment, and that this risk is increased if dosing instructions are not carefully followed. Tell patients not to drive a car or engage in hazardous activities requiring complete alertness until they experience how the drug affects them the next day. Tell patients that if they took IMOVANE as instructed and do not feel drowsy in the morning, they still have to wait for at least 12 hours after dosing before driving or engaging in other activities requiring full mental alertness, especially for elderly patients and for patients who take the 7.5 mg dose. Inform patients that impairment can be present despite feeling fully awake.

**Falls and Fractures**

There have been reports of falls and fractures among users of benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, due to adverse reactions such as sedation, dizziness and ataxia. The risk is increased in those taking concomitant sedatives (including alcoholic beverages), geriatric or debilitated patients.

**Hepatic/Biliary/Pancreatic**

Patients with specific conditions: IMOVANE should be given with caution to patients with impaired hepatic or renal function. Dosage adjustments are recommended (see 4 DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment).

IMOVANE is contraindicated in patients with severe hepatic insufficiency (see 2 CONTRAINDICATIONS).

**Immune**

Severe Anaphylactic and Anaphylactoid Reactions: Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including IMOVANE. Some patients have had additional symptoms such as dyspnea, throat
closing or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with IMOVANE should not be rechallenged with the drug.

**Patients with specific conditions:** IMOVANE is contraindicated in patients with myasthenia gravis (see 2 CONTRAINDICATIONS).

**Lactose**

Lactose is a non-medicinal ingredient in IMOVANE 5 mg. Patients with rare hereditary diseases of galactose intolerance (galactosemia or glucose-galactose malabsorption) should not take IMOVANE 5 mg. IMOVANE 7.5 mg does not contain lactose (see 4 DOSAGE AND ADMINISTRATION and 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).

**Neurologic**

**Abnormal thinking and behavioural changes:** Abnormal thinking and other behavioural changes have been reported to occur in association with the use of benzodiazepines and benzodiazepine-like agents including IMOVANE, although rarely (see 8 ADVERSE REACTIONS). Some of the changes may be characterized by decreased inhibition, e.g., aggression or extroversion that seems excessive, similar to that seen with alcohol and other CNS depressants (e.g., sedative/hypnotics). Particular caution is warranted in patients with a history of violent behaviour and a history of unusual reactions to sedatives including alcohol and the benzodiazepines or benzodiazepine-like agents. Psychotic behavioural changes that have been reported include abnormal behaviour, restlessness, agitation, irritability, hallucinations, delusion, anger, nightmares, delirium and depersonalization. Abnormal behaviours associated with the use of benzodiazepines or benzodiazepine-like agents have been reported more with chronic use and/or high doses but they may occur during the acute, maintenance or withdrawal phases of treatment.

It can rarely be determined with certainty whether a particular instance of abnormal behaviours listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric disorder. Nevertheless, the emergence of any new behavioural sign or symptom of concern requires careful and immediate evaluation. Should these occur, use of the product should be discontinued. These reactions are more likely to occur in the elderly.

**Amnesia:** Anterograde amnesia of varying severity has been reported following therapeutic doses of benzodiazepines or benzodiazepine-like agents. The event is rare with IMOVANE. Anterograde amnesia may occur, especially when sleep is interrupted or when retiring to bed is delayed after the intake of the tablet. Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

Cases of transient global amnesia and “traveler’s amnesia” have also been reported in association with benzodiazepines, the latter in individuals who have taken the drug, often in the middle of the night, to induce sleep while travelling. Transient global amnesia and traveler’s amnesia are unpredictable and not necessarily dose-related phenomena.

To reduce the possibility of anterograde amnesia, patients should ensure that they take the tablet strictly when retiring for the night. Patients should be warned not to take IMOVANE under circumstances in which a full night’s sleep and clearance of the drug from the body are not possible before they need again to resume full activity.

**Cognitive Function:** The benzodiazepines and benzodiazepine-like agents affect mental efficiency, e.g.,
concentration, attention and vigilance. The risk of confusion is greater in the elderly and in patients with cerebral impairment.

**Psychiatric:**

**Anxiety, restlessness:** An increase in daytime anxiety and/or restlessness has been observed during treatment with IMOVANE. This may be a manifestation of interdose withdrawal, due to the short elimination half-life of the drug.

**Depression:** Caution should be exercised if IMOVANE is prescribed to patients with signs and symptoms of depression that could be intensified by hypnotic drugs. The potential for self-harm (e.g., intentional overdose) is high in patients with depression and thus, the least amount of drug that is feasible should be available to them at any one time.

As with other hypnotics, IMOVANE does not constitute a treatment of depression and may even mask its symptoms

**Suicidality and Depression:** Several epidemiological studies show an increased incidence of suicide and suicide attempt in patients with or without depression, treated with benzodiazepines and other hypnotics, including zopiclone. A causal relationship has not been established.

As with other sedative-hypnotic drugs, IMOVANE should be administered with caution in patients exhibiting symptoms of depression. Suicidal tendencies may be present, therefore the lowest possible quantity of IMOVANE should be supplied to these patients to reduce the risk of intentional overdose by the patient. Since insomnia may be a symptom of depression, the patient should be re-evaluated if insomnia persists. In these patients, more direct monitoring of suicidal thinking may be warranted.

**Respiratory**

**Patients with specific conditions:** IMOVANE should be given with caution to patients with chronic pulmonary insufficiency. Dosage adjustments are recommended (see 4 DOSAGE AND ADMINISTRATION). Respiratory depression has been reported in patients with compromised respiratory function. As hypnotics have the capacity to depress respiratory drive, precautions should be observed if IMOVANE is prescribed to patients with compromised respiratory function.

IMOVANE is contraindicated in patients with severe impairment of respiratory function, e.g., significant sleep apnea syndrome (see 2 CONTRAINDICATIONS).

7.1 Special Populations

7.1.1 Pregnant Women

The use of IMOVANE during pregnancy is not recommended.

If IMOVANE is prescribed to a woman of child-bearing potential, the patient should be warned of the potential risk to a fetus and advised to consult her physician regarding the discontinuation of the drug if she intends to become pregnant or suspects that she is pregnant.

Zopiclone crosses the placenta.

Benzodiazepines may cause fetal damage when administered during pregnancy. During the first trimester of pregnancy, several studies have suggested an increased risk of congenital malformations associated with the use of benzodiazepines. In certain epidemiological case-control studies, an increased incidence of cleft lip and palate was observed with benzodiazepines.
During the last weeks of pregnancy or during labor, ingestion of therapeutic doses of benzodiazepine hypnotic drugs has resulted in neonatal CNS depression due to transplacental distribution. Similar effects can be expected to occur with zopiclone, due to its pharmacological effects. Cases of reduced fetal movement and fetal heart rate variability have been described after administration of benzodiazepines during the second and/or third trimester of pregnancy.

Administration of IMOVANE during the late phase of pregnancy or during labor has been associated with effects on the neonate, such as hypothermia, hypotonia, feeding difficulties (which may result in poor weight gain) and respiratory depression.

A child born to a mother who took sedative/hypnotics agents chronically during the latter stages of pregnancy may have developed physical dependence and may be at risk for developing withdrawal symptoms in the postnatal period. Appropriate monitoring of the newborn in the postnatal period is recommended.

7.1.2 Breast-feeding

IMOVANE is excreted in human milk, and its concentration may reach 50% of the plasma levels. Insufficient data are available on IMOVANE to assess its safety during lactation. Therefore, the administration of IMOVANE to nursing mothers is not recommended.

7.1.3 Pediatrics (< 18 years of age):

The safety and efficacy of IMOVANE in children and young adults below the age of 18 have not been established. IMOVANE should not be prescribed in pediatric patients.

7.1.4 Geriatrics (≥ 65 years of age):

Elderly patients are especially susceptible to dose-related adverse effects, such as drowsiness, dizziness, or impaired coordination. Inappropriate, heavy sedation may result in accidental events/fall. Therefore, the IMOVANE dose in elderly patients should not exceed 5 (see 4 DOSAGE AND ADMINISTRATION, 1.2 Geriatrics (≥ 65 years of age)). Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

Long-term use of IMOVANE should be avoided, including in geriatric patients or debilitated patients who may be more sensitive to IMOVANE. There is an increased risk of cognitive impairment, delirium, falls, fractures, hospitalizations and motor vehicle accidents in these users. Enhanced monitoring is recommended in this population.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The most common adverse reaction seen with IMOVANE is taste alteration (bitter taste). Severe drowsiness and/or impaired coordination are signs of drug intolerance or excessive doses.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to
the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

The following adverse events were observed in patients receiving IMOVANE. In the absence of an established cause-effect relationship those adverse reactions that were observed more frequently with IMOVANE than with a placebo are in italic.

| Central Nervous System: | Somnolence, dizziness, confusion, anterograde amnesia or memory impairment, feeling of drunkenness, euphoria, nightmares, agitation, anxiety or nervousness, hostility, depression, decreased libido, libido disorder, coordination abnormality, headache, hypotonia, tremor, muscle spasms, paresthesia, and speech disorder. Hallucinations, aggression, irritability and fall (predominantly in elderly patients). |
| Cardiovascular: | palpitations |
| Digestive: | dysgeusia (bitter taste), dry mouth, coated tongue, bad breath, nausea, vomiting, diarrhea, constipation, anorexia or increased appetite |
| General Disorders and Administration Site Conditions: | asthenia, chills, fatigue |
| Respiratory: | dyspnea |
| Special senses: | amblyopia |
| Dermatologic: | rash, spots on skin, sweating, pruritus. Rashes and pruritus may be a sign of drug hypersensitivity; discontinue if this occurs. Angioedema and/or anaphylactic reactions have been reported very rarely. |
| Metabolic and nutritional: | weight loss |
| Musculoskeletal: | limb heaviness |

**Geriatric patients**
Geriatric patients tended to have a higher incidence of palpitations, vomiting, anorexia, sialorrhea, confusion, agitation, anxiety, tremor and sweating than younger patients. Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

**Withdrawal symptoms:**
Withdrawal syndrome has been reported upon discontinuation of IMOVANE (see 7 WARNINGS AND PRECAUTIONS, Withdrawal). Withdrawal symptoms vary and may include rebound insomnia, muscle pain, anxiety, tremor, sweating, agitation, confusion, headache, palpitations, tachycardia, delirium, nightmares, irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations. In very rare cases, seizures may occur.
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

Laboratory tests: There have been sporadic reports of abnormal laboratory test values. Mild to moderate increases in serum transaminase and/or blood alkaline phosphatase have been reported very rarely.

8.5 Post-Market Adverse Reactions

Injury, Poisoning and Procedural Complications: There have been reports of falls and fractures in users of benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, due to adverse reactions such as sedation, dizziness and ataxia. The risk is increased in those taking concomitant sedatives (including alcoholic beverages), geriatric and debilitated patients.

Dependence/Withdrawal: Development of physical dependence and withdrawal following discontinuation of therapy has been observed with benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE. Severe and life-threatening symptoms have been reported. (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Addiction, Abuse and Misuse; 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance).

Psychiatric disorders: restlessness, delirium, delusion, anger, abnormal behaviours (possibly associated with amnesia), complex sleep behaviours including somnambulism (see 7 WARNINGS AND PRECAUTIONS, Complex sleep behaviours), withdrawal syndrome and dependence have been reported rarely.

Respiratory disorders: respiratory depression

Nervous system disorder: ataxia, paresthesia (not associated with withdrawal), disturbance in attention

Eye disorder: diplopia

Gastrointestinal disorders: dyspepsia
Musculoskeletal and connective tissue disorders:

muscular weakness.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

<table>
<thead>
<tr>
<th>Serious Drug Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant use of IMOVANE and opioids may result in profound sedation, respiratory depression, coma and death.</td>
</tr>
<tr>
<td>- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are not possible.</td>
</tr>
<tr>
<td>- Limit dosages and durations to the minimum required.</td>
</tr>
<tr>
<td>- Follow patients for signs and symptoms of respiratory depression and sedation.</td>
</tr>
<tr>
<td>(see 7 WARNINGS AND PRECAUTIONS, General, Risks from Concomitant Use with Opioids)</td>
</tr>
</tbody>
</table>

9.2 Drug Interactions Overview

The risk of drug interaction arising from displacement of bound drug is low.

IMOVANE may produce additive CNS depressant effects when co-administered with alcohol, sedative antihistamines, anticonvulsants, narcotic analgesics, anesthetics, or psychotropic medications which themselves can produce CNS depression (see 9.3 Drug-Behavioural Interactions; 9.4 Drug-Drug Interactions).

The activity of IMOVANE may be increased or decreased when co-administered with CYP3A4 inhibitors or inducers respectively (see 9.4 Drug-Drug Interactions).

9.3 Drug-Behavioural Interactions

Alcohol

Concomitant intake with alcohol is not recommended (see 7 WARNINGS AND PRECAUTIONS, Complex sleep behaviours). IMOVANE may produce additive CNS depressant effects when co-administered with alcohol.

9.4 Drug-Drug Interactions

CNS Depressants

IMOVANE may produce additive CNS depressant effects when co-administered with sedative antihistamines, anticonvulsants, narcotic analgesics, anesthetics, or psychotropic medications such as antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, and antidepressant agents which themselves can produce CNS depression. In the case of narcotic analgesics, enhancement of euphoria may also occur, leading to an increase in psychological dependence.

Drugs Affecting Cytochrome P450 Enzymes
Since IMOVANE is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme (see 10 CLINICAL PHARMACOLOGY, Pharmacokinetics, Metabolism), plasma levels of IMOVANE may be increased when co-administered with CYP3A4 inhibitors, such as erythromycin, clarithromycin, ketoconazole, itraconazole, and ritonavir. A dose reduction for IMOVANE may be required when it is co-administered with CYP3A4 inhibitors. Conversely, plasma levels of IMOVANE may be decreased when co-administered with CYP3A4 inducers, such as rifampicin or rifampin, carbamazepine, phenobarbital, phenytoin, and St. John’s wort. A dose increase for IMOVANE may be required when it is co-administered with CYP3A4 inducers (see 7 WARNINGS AND PRECAUTIONS).

The effect of erythromycin on the pharmacokinetics of IMOVANE has been studied in 10 healthy subjects. The AUC of IMOVANE is increased by 80% in presence of erythromycin, a possible consequence of erythromycin inhibition of IMOVANE metabolism by CYP3A4. As a consequence, the hypnotic effect of IMOVANE may be enhanced when administered with erythromycin or other CYP3A4 inhibitors.

**Opioids**

Due to additive CNS depressant effect, the concomitant use of benzodiazepines or other CNS depressants, including IMOVANE, and opioids increases the risk of profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations of concomitant use of benzodiazepines and opioids to the minimum required. Follow patients closely for respiratory depression and sedation (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, and 7 WARNINGS AND PRECAUTIONS, Concomitant Use with Opioids).

**9.5 Drug-Food Interactions**

Interactions with food have not been established.

**9.6 Drug-Herb Interactions**

Plasma levels of IMOVANE may be decreased when co-administered with St. John’s wort.

**9.7 Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.

**10 CLINICAL PHARMACOLOGY**

**10.1 Mechanism of Action**

IMOVANE (zopiclone), a cyclopyrrolone derivative, is a short-acting hypnotic agent. IMOVANE is structurally unrelated to existing hypnotics. However, the pharmacological profile of IMOVANE is similar to that of the benzodiazepines.

IMOVANE pharmacological properties are: hypnotic, sedative, anxiolytic, anti-convulsant, muscle-relaxant. These effects are related to a specific agonist action at central receptors belonging to the GABAA macromolecular complex, modulating the opening of the chloride ion channel.
CNS Activity

Zopiclone antagonizes chemically and electroshock-induced seizures in mice and rats. While it potently affects convulsive conditions that involve GABA, it is relatively ineffective when glycine, another inhibitory amino acid, is involved.

Zopiclone exerts muscle relaxant activity; it inhibits the traction grasping reflex in mice, reduces the ability of mice and rats to remain on a rotarod and inclined screen, respectively, relaxes the hind legs of normal cats and blocks polysynaptic reflexes in chloralosed cats.

Zopiclone also exerts antiaggressive activity; it inhibits footshock-induced fighting behaviour in mice and septal lesion-induced aggression in rats.

In a “conflict” situation, the drug increases punishment-suppressed lever-pressing behaviour, which is indicative of anxiolytic activity. Non-punished responding, indicative of non-specific sedation, is suppressed only at higher doses.

While zopiclone does not cause loss of righting reflex in normal mice, it potentiates narcosis induced by hexobarbital or ethanol.

In a drug discrimination paradigm, where rats are trained to discriminate drug from saline, the zopiclone discriminative stimulus generalized to several benzodiazepines as well as to pentobarbital. The finding that the benzodiazepines and a barbiturate were able to substitute for zopiclone indicates that zopiclone belongs to the same class of drugs.

Tolerance does not develop to the behavioural effects of zopiclone, since the anticonvulsant and taming ED50’s are similar in naive and zopiclone-treated animals.

Receptor binding studies

Zopiclone has a high and specific affinity for benzodiazepine binding sites in several rat brain regions. The drug can inhibit the binding of 3H-benzodiazepines, but can itself label the sites that are recognized both by benzodiazepine agonists and Ro 15-1788, a benzodiazepine antagonist. Zopiclone does not recognize the peripheral benzodiazepine receptor sites and lacks affinity for the serotonin, GABA, $\alpha_1$ and $\alpha_2$ adrenergic, and dopamine receptors.

The interaction of zopiclone with the benzodiazepine receptor/GABA receptor/chloride channel complex differs somewhat from that of the benzodiazepines; while it decreases cGMP concentration in rat cerebellum, its binding is not enhanced either by GABA or by the chloride anion.

Dependence Liability

In barbital-dependent rhesus monkeys, zopiclone suppressed the abstinence symptoms which appeared upon withdrawal. Partial and complete suppression was observed at 4 and 16 mg/kg doses, respectively.

Zopiclone, when administered to monkeys at a dose of 16 mg/kg/day for 28 days, precipitated withdrawal signs of moderate severity. Peak symptoms appeared three and four days after withdrawal and included hyperirritability, restlessness, tremor, and some weight loss. The administration of a higher dose for two weeks brought about similar symptoms upon withdrawal without precipitating convulsions.

Zopiclone was self-administered both intravenously and intragastrically in monkeys. When the drug was changed to saline, the rate of self-administration declined rapidly.
Cardiovascular and Respiratory Effects

Zopiclone was evaluated in conscious and anesthetized cats, dogs, rabbits and monkeys with regard to its effect on respiration and several cardiovascular parameters. Most of the studies involved i.v. administration.

In general, respiration and blood pressure decreased in a dose-dependent fashion while heart rate and EKG showed little change. Zopiclone affected central respiratory control mechanisms to a greater extent than the cardiovascular regulatory mechanisms.

Drug-Interaction Studies

Zopiclone was evaluated in combination with several drugs and in general interacted either in an additive or synergistic fashion with diazepam, phenobarbital, trimethadione, chlorpromazine, hexobarbital, and ethanol. Zopiclone did not modify the effects of phenytoin, morphine, ketoprofen and gallamine.

The effects of zopiclone could be reversed by Ro 15-1788 (flumazenil) a specific benzodiazepine antagonist.

10.2 Pharmacodynamics

In sleep laboratory studies of one to 21-day duration in man, zopiclone reduced sleep latency, increased the duration of sleep and decreased the number of nocturnal awakenings. Zopiclone delayed the onset of REM sleep but did not reduce consistently the total duration of REM periods. The duration of stage 1 sleep was shortened, and the time spent in stage 2 sleep increased. In most studies, stage 3 and 4 sleep tended to be increased, but no change and actual decreases have also been observed. The effect of zopiclone on stage 3 and 4 sleep differs from that of the benzodiazepines, which suppress slow wave sleep. The clinical significance of this finding is not known.

With hypnotic drugs, the duration of hypnotic effect and the profile of unwanted effects may be influenced by the alpha (distribution) (t½α) and beta (elimination) (t½β) half-lives of the administered drug and any active metabolites formed. When half-lives are long, the drug or metabolite may accumulate during periods of nightly administration and be associated with impairments of cognitive and motor performance during waking hours. If half-lives are short, the drug and metabolites will be cleared before the next dose is ingested, and carry-over effects related to sedation or CNS depression should be minimal or absent. If the drug has a very short elimination half-life, it is possible that a relative deficiency (i.e., in relation to the receptor site) may occur at some point in the interval between each night’s use. This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepines or benzodiazepine-like hypnotics: 1) increased wakefulness during the last third of the night and 2) the appearance of increased day-time anxiety (see 7 WARNINGS AND PRECAUTIONS).

During nightly use and for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepines or benzodiazepine-like hypnotics may develop. However in two sleep laboratory studies involving 17 patients, there was an absence of tolerance with zopiclone for treatment periods of more than 4 weeks.

Rebound insomnia: Some manifestations of rebound insomnia have been reported both in sleep laboratory and clinical studies following the withdrawal of zopiclone (see 7 WARNINGS AND PRECAUTIONS).

Zopiclone treatment was associated with dose-related residual effects (see 7 WARNINGS AND
10.3 Pharmacokinetics

Absorption

Zopiclone is rapidly and well absorbed. Bioavailability is more than 75%, indicating the absence of a significant first-pass effect. After the administration of 3.75 and 7.5 mg doses, peak plasma concentrations of 30 and 60 ng/mL, respectively were reached in less than 2 hours. Absorption was similar in males and females.

Repeated daily administration of a 7.5 mg oral dose for 14 days did not change the pharmacokinetic characteristics of zopiclone and did not lead to accumulation.

Distribution:

Zopiclone is rapidly distributed from the vascular compartment (distribution half-life \[t_{\alpha}\]: 1.2 hours) while the elimination half-life is approximately 5 hours (range: 3.8 to 6.5 hours). Plasma protein binding is low (approximately 45% in the 25-100 ng/mL concentration range) and non saturable. The risk of drug interaction arising from displacement of bound drug is low. The distribution volume is 91.8-104.6 liters.

Metabolism:

Zopiclone is extensively metabolized by three major pathways; only about 4 to 5% of the drug is excreted unchanged in the urine.

An in vitro study indicates that cytochrome P450 (CYP) 3A4 is the major isoenzyme involved in the metabolism of zopiclone to both metabolites, and that CYP2C8 is also involved with N-desmethyl zopiclone formation.

The principal metabolites are the N-oxide derivative (~12%), which has weak pharmacological activity in animals, and the N-desmethyl metabolite (~16%), which is pharmacologically inactive.

Their apparent half-lives evaluated from the urinary data are approximately 4.5 and 7.4 hours, respectively. Both metabolites are excreted renally.

Other metabolites resulting from oxidative decarboxylation are partly eliminated via the lung as carbon dioxide. In animals, zopiclone did not induce hepatic microsomal enzymes.

Elimination

Excretion studies, using C\(^{14}\)-zopiclone have shown that more than 90% of the administered dose was excreted over a period of 5 days, 75% being eliminated in the urine and 16% in the feces.

The low renal clearance of unchanged zopiclone (mean 8.4 mL/min) compared with that of plasma (232 mL/min) indicates that zopiclone clearance is mainly metabolic.

Special Populations and Conditions

- **Pediatrics**: IMOVANE is not indicated for patients under 18 years of age.
• **Geriatrics:** the absolute bioavailability of zopiclone was increased (94% vs 77% in young subjects) and the elimination half-life prolonged (~7 hours). Accumulation has not been observed on repeated dosing.

• **Pregnancy and Breast-feeding:** zopiclone was present in the milk, its concentration paralleled plasma levels but was about 50% lower (see 7 WARNINGS AND PRECAUTIONS)

• **Hepatic Insufficiency:** elimination half-life was substantially prolonged (11.9 hours) and time to peak plasma levels delayed (3.5 hours). Consequently, lower doses are recommended (see 4 DOSAGE AND ADMINISTRATION).

  In cirrhotic patients, the plasma clearance of IMOVANE is reduced by approximately 40% in relation with the decrease of the demethylation process. Therefore, dosage will have to be modified in these patients.

• **Renal Insufficiency:** the pharmacokinetics of zopiclone were not affected by mild to moderate renal insufficiency. In renal insufficiency, no accumulation of zopiclone or of its metabolites has been detected after prolonged administration.

  IMOVANE is removed by hemodialysis; however, hemodialysis is of no value in treating overdose due to the large volume of distribution of IMOVANE (see also 5 OVERDOSAGE). Hemodialysis did not appear to increase the plasma clearance of the drug.

11 **STORAGE, STABILITY AND DISPOSAL**

Store in a dry place, at room temperature (15°-30°C). Protect from light.

Keep in a safe place out of reach of children.

12 **SPECIAL HANDLING INSTRUCTIONS**

No special handing instructions information is required for this drug product.
PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Zopiclone
Chemical name: \((5RS)-6-(5\text{-choloropyridin}-2\text{-yl})-7\text{-oxo}-6,7\text{-dihydro-5H-pyrrolo}[3,4-b]pyrazin-5\text{-yl} 4\text{-methylpiperazine-1-carboxylate}\)
Molecular formula and molecular mass: \(\text{C}_{17}\text{H}_{17}\text{ClN}_{6}\text{O}_{3}\) and 388.8

Structural formula:

![](image)

Physicochemical properties: A white or slightly yellowish powder, practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in acetone, practically insoluble in alcohol. It dissolves in dilute mineral acids.

It melts at about 177 °C, with decomposition.
14 CLINICAL TRIALS

Data on which indications were initially approved is not available.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute

Studies were carried out in both sexes of several species. The results are summarized in the Table.

<table>
<thead>
<tr>
<th>SPECIES</th>
<th>ROUTE</th>
<th>LD$_{50}$ (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>i.v.</td>
<td>450</td>
</tr>
<tr>
<td></td>
<td>i.p.</td>
<td>580</td>
</tr>
<tr>
<td></td>
<td>p.o.</td>
<td>1150</td>
</tr>
<tr>
<td>Rats</td>
<td>p.o.</td>
<td>2300</td>
</tr>
<tr>
<td>Dogs</td>
<td>p.o.</td>
<td>≥ 4500</td>
</tr>
<tr>
<td></td>
<td>i.v.</td>
<td>~ 400</td>
</tr>
<tr>
<td>Cats</td>
<td>p.o.</td>
<td>&gt; 1500</td>
</tr>
<tr>
<td>Rabbits</td>
<td>p.o.</td>
<td>~ 2500</td>
</tr>
<tr>
<td>Monkeys</td>
<td>p.o.</td>
<td>&gt; 4500</td>
</tr>
</tbody>
</table>

Symptoms of toxicity included sedation, CNS depression, ataxia, respiratory depression, and dyspnea. In dogs, the i.v. administration of zopiclone was followed by myoclonic seizures.

Long-Term

Rats (CD Strain):

One-month oral study

Ten rats/sex/dose received zopiclone by gavage six days per week at doses of 0, 6, 24 and 120 mg/kg. Dose-related sedation and paresis of hind legs were observed.

Thyroid weights were increased in male rats at all dose levels. In the high dose males, heart and spleen weights were reduced.

Three-month oral study

Fifteen rats/sex/dose received zopiclone by gavage seven days per week at doses of 0, 2, 12 and 120 mg/kg. At the mid and high doses, dose-related hypotonia, adynamia and ptosis were observed, all of
which subsided with time. Weight gain was slightly but significantly less in mid and high dose male rats than in controls.

At the 120 mg/kg dose the following changes occurred. BSP values decreased in both sexes; the number of RBC decreased in females; liver weights increased in both males and females, accompanied by slight changes in the parenchymal liver cells, namely eosinophilia or basophilia in the portal area.

18-month oral study
Fifty rats/sex/dose received zopiclone in the diet at doses of 0, 2, 20 and 200 mg/kg. Of these animals 15 rats/sex/dose were sacrificed at six months. The lowest dose was well tolerated.

At the high dose the following changes were seen: weight gain was reduced by about 30% in both sexes; plasma protein levels were elevated at 3 and 6 months in the males and throughout the study in the females; albumin and globulin levels were elevated; thyroid weights were increased in male rats, accompanied by thyroid hyperplasia and, in some rats, by follicular adenomas; liver weights were increased in female rats both at 6 and 18 months; hepatocellular hypertrophy occurred in both sexes.

Dogs (Beagle):

One-month oral study
One dog/sex/dose received zopiclone six days per week at doses of 0, 6, 24 and 120 mg/kg. Dose-related sedation and hypotonia of the hind legs were observed. High dose dogs and the intermediate dose female dog exhibited moderate weight loss.

At the high dose, both dogs had Heinz bodies in circulating erythrocytes and the bone marrow showed erythoblastic hyperplasia. In addition, the male animal had marked anemia and active erythropoiesis in the spleen. BUN values were increased at all doses in a dose-related fashion; liver function tests were somewhat elevated.

Six-month oral study
Six dogs/sex/dose received zopiclone seven days per week at doses of 0, 5, 10 and 25 mg/kg. One dog/sex from each group was sacrificed after a 3-month recovery period. Zopiclone caused slight excitation, ataxia and drowsiness, and drowsiness and sleep at the 5, 10, and 25 mg/kg doses respectively. Late in the study, four dogs had epileptoid seizures and three of them died. A reduced weight gain was observed only in high dose male dogs.

Platelet counts rose substantially above normal in two high dose female dogs. Transaminase levels were elevated but not in a dose-dependent manner. Alkaline phosphatase levels were significantly elevated both in male and female dogs, receiving the 25 mg/kg dose.

While liver weights increased both in male and female dogs in a dose-dependent fashion, they returned toward control values following the 3-month recovery period. In high dose male animals, relative spleen, kidney and adrenal weights were significantly increased. Examination of bone marrow smears showed that the proportion of proerythroblasts and the ratio of normoblasts to basophilic erythroblasts were significantly greater in high dose females than in controls.

One-year oral study
Five dogs/sex/dose received zopiclone seven days per week at doses of 0, 1, 5 and 25 mg/kg. Zopiclone induced ataxia, sleepiness, lethargy, decreased activity, body tremors and excitability. The latter two effects occurred prior to dosing, while the others were seen shortly after dosing. After six months of treatment, zopiclone induced epileptoid seizures in five dogs (four high dose, one mid dose). Since the
convulsions were observed early morning prior to dosing, they might have been a manifestation of withdrawal. Female dogs, treated with 5 mg/kg of zopiclone, were significantly heavier than controls. Treated animals both ate and drank more than did their respective controls.

Platelet counts were elevated in both sexes at the 5 and 25 mg/kg doses. Alkaline phosphatase was elevated from the first month on in mid and high dose animals. T4 values in high dose males and BSP values in high dose females were also elevated.

There was a dose-dependent increase in liver weights which became statistically significant at the 25 mg/kg dose. The elevated liver weights were associated with histopathological changes, namely vacuolation of hepatocyte cytoplasm with eosinophilic hyaline bodies.

**Carcinogenicity:**

Oncogenicity studies were carried out with zopiclone in rats and mice with doses of 1, 10, 100 mg/kg/day for two years. There was an increased incidence of mammary tumours with a shift toward more anaplastic forms in female and an increase of thyroid tumours in male rats on the high dose. In the mouse study, females on the high dose had an increased incidence of pulmonary adenocarcinomas; while males on the high dose had a high number of subcutaneous soft tissue tumours.

In a wide battery of tests, it was shown that zopiclone has no mutagenic or clastogenic (chromosome-damaging) properties; urine extracts from zopiclone treated mice, rats and humans were similarly not mutagenic.

The effect of zopiclone is that of a non-genotoxic oncogen; tumor redistribution phenomena are frequently observed in rodent carcinogenicity studies, particularly with drugs acting on the central nervous system and the hormonal balance. The rise of 17 beta-estradiol may be regarded as a cause for the emergence of mammary tumours and the shift from well differentiated to poorly differentiated mammary carcinomas. The altered feedback mechanism following accelerated clearance of T4 and the rise of TSH is responsible for thyroid overstimulation that leads to formation of thyroid neoplasms. The soft tissue tumours of male mice are brought about by fighting (a paradoxical reaction) and subsequent initiation by encrustation and foreign body reaction. The increased incidence of pulmonary adenocarcinomas in female mice may be regarded as fortuitous (“chance finding”), but there is not enough data available to exclude some other mechanisms.

No comparable endocrine changes were observed in man given the therapeutic dose of zopiclone (7.5 mg). The tumor producing dose of zopiclone represents 800 times and the no effect level 80 times the proposed human dose (0.125 mg/kg).

**Mutagenicity:**

Zopiclone and its metabolic products were tested for mutagenic potential in the following assays:
<table>
<thead>
<tr>
<th>ASSAY</th>
<th>INDICATOR SPECIES OR ORGANISM</th>
<th>DOSES USED</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ames’ test</strong></td>
<td><strong>Salmonella typhimurium</strong> <em>(TA98, TA100, TA1535, TA1537 &amp; TA 1538)</em> <strong>Escherichia coli</strong> <em>(WP2 uvrA)</em></td>
<td>Up to 500 mcg/plate with or without rat liver microsome activating enzymes.</td>
</tr>
<tr>
<td><strong>Ames’ test</strong></td>
<td><strong>Salmonella typhimurium</strong> <em>(5 strains as above)</em></td>
<td>Concentrated urine extracts from rats treated at 1, 10 and 100 mg/kg for 20 days.</td>
</tr>
<tr>
<td><strong>Ames’ test</strong></td>
<td><strong>Salmonella typhimurium</strong> <em>(5 strains as above)</em></td>
<td>Up to 5000 mcg/plate with liver microsomal enzymes from B6C3F1 mice.</td>
</tr>
<tr>
<td><strong>Ames’ test</strong></td>
<td><strong>Salmonella typhimurium</strong> <em>(5 strains as above)</em> <strong>Escherichia coli</strong> <em>(WP2 uvrA)</em></td>
<td>1) Urine samples from volunteers receiving 7.5, 10 or 15 mg with or without liver microsomal enzymes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Two major metabolites, N-oxide and N-desmethyl derivatives: up to 1000 mcg/plate.</td>
</tr>
<tr>
<td><strong>In vitro and In vivo host mediated assay</strong></td>
<td><strong>Saccharomyces cerevisiae</strong> <em>(D7)</em></td>
<td><em>In vitro</em>: up to 1000 mcg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>In vivo</em>, in mice: 100 mg/kg p.o.</td>
</tr>
<tr>
<td><strong>Gene forward mutation test</strong></td>
<td><strong>Chinese Hamster Ovary cells</strong> <em>(CHO/HG PRT)</em></td>
<td>Up to 200 mcg/mL with or without metabolic activation.</td>
</tr>
<tr>
<td><strong>In vitro mammalian cell test for clastogenicity.</strong></td>
<td><strong>Chinese Hamster Ovary cells</strong> <em>(CHO/K1 line)</em></td>
<td>Up to 200 mcg/mL with or without metabolic activation.</td>
</tr>
<tr>
<td><strong>DNA repair Assay</strong> <em>(William’s test)</em></td>
<td><strong>Primary cultures of rat hepatocytes</strong></td>
<td>Up to $10^{-4}$ M.</td>
</tr>
<tr>
<td><strong>Dominant lethal test</strong></td>
<td><strong>Rats and mice</strong></td>
<td>Up to 120 mg/kg/day p.o.</td>
</tr>
<tr>
<td><strong>Micronucleus test</strong></td>
<td><strong>Mice</strong></td>
<td>Up to 630 mg/kg/day p.o.</td>
</tr>
<tr>
<td><strong>Sex-linked recessive lethal test</strong></td>
<td><strong>Drosophila melanogaster cells</strong> <em>(CHO/HG PRT)</em></td>
<td>2% solution p.o. activation.</td>
</tr>
</tbody>
</table>

All tests were negative. Zopiclone was neither a mutagen nor a clastogen and did not give rise to mutagenic metabolites either in experimental animals or in man.

Reproductive and Developmental Toxicology:
Fertility and general reproductive performance
The effect of zopiclone was evaluated in three studies. First, treated male rats were mated with treated female rats, the oral doses of zopiclone being 0, 2, 12 and 120 mg/kg. The males were treated for 10 weeks prior to mating, the females for 2 weeks prior to mating, during pregnancy and throughout a 3-week lactation period. In two further experiments, treated males (120 mg/kg) were mated with untreated females and untreated males were mated with treated females (120 mg/kg). Both of the latter experimental conditions included a control group.

Rate of pregnancy, number of implantations, rate of resorption and number of live fetuses were similar in control and low and medium dose-treated rats. However, mortality of pups was significantly higher in the mid dose group than in the control group.

At the 120 mg/kg dose, regardless whether treated males were mated with treated or untreated females, only ~10% of the females became pregnant and even in these animals resorption was complete. When high dose-treated females were mated with untreated males, the rate of pregnancy was only slightly lower than in controls (83% vs 100%) and all pregnant females delivered live fetuses. Survival of fetuses, up to day 21 of lactation, was significantly lower than in controls.

In conclusion, 120 mg/kg dose of zopiclone induces sterility in male animals, while in females it affects pregnancy rate only slightly. Up to 12 mg/kg, the drug does not affect fertility and reproductive functions.

Teratology - rats

The study was performed in groups of 20 rats each, given zopiclone orally at doses of 0, 5, 25 and 125 mg/kg from day 5 to day 15 of gestation. In rats treated with the high dose of zopiclone, the following changes were seen when compared to the controls: food intake and final body weight (day 20) were slightly but significantly lower, the rate of resorption was somewhat higher (9% vs 6%) and the mean weight of live fetuses slightly but significantly lower (3.5 g vs 3.7 g). One pup had a sternal malformation, and five pups from the same mother had asymmetrical sternabrae. Both anomalies occur in the strain used. In conclusion, zopiclone is not teratogenic in rats in doses up to 125 mg/kg.

Teratology - rabbits

The study was performed in groups of 16 rabbits each given zopiclone orally at doses of 0, 5, 25 and 125 mg/kg from day 6 to day 16 of gestation. Food intake and weight gain were significantly affected and in a dose-related manner. At the 125 mg/kg dose, the rabbits actually lost some weight by the end of treatment. The mean weight of live fetuses in this group was significantly lower than in the controls (31.5 g vs 35.8 g). Three of the fetuses were malformed, 1/109 live fetuses in the mid dose and 2/129 live fetuses in the high dose, exhibiting malformations of the urinary tract, exencephaly and forelimbs with clubfeet and malformations of the large heart vessels, respectively. These malformations do occur in the strain used. In conclusion, zopiclone is not teratogenic in rabbits in doses up to 125 mg/kg.

Perinatal and postnatal study

This was a two generation study in which male and female offsprings (F1 generation) of treated mothers were bred and the F2 generation also observed.

Zopiclone was given orally at doses of 0, 10, 50 and 250 mg/kg from day 17 of gestation to day 28 of lactation. The following significant changes were observed: smaller litter size in the high dose group, lower body weights at birth and at weaning in the mid and high dose groups, dose-related increase of mortality at birth and between days 1 and 28. Mortality during lactation was significantly different from control even in the 10 mg/kg group. Cannibalization of pups increased in a dose-related manner; this effect might have been due to the fact that the pups were sedated, hypothermic and had problems
with suckling.

Gross behaviour, physical development, auditory function, spontaneous motor activity and learning behaviour were normal in the surviving F1 pups. Males and females from the F1 generation mated successfully except for three rats which were infertile (one male rat from the 50 mg/kg group and one male and one female rat from the 250 mg/kg group). The male rat from the mid dose group had bilateral hypoplastic testes and epididymis. Mortality and weights of the F2 generation were within the normal range for the strain used. One F2 pup, from the mid dose group, had oligodactyly with syndactyly of the left forelimb.
PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr IMOVANE®

Zopiclone tablets

Read this carefully before you start taking IMOVANE and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about IMOVANE.

Serious Warnings and Precautions

Addiction, Abuse and Misuse: Even if you take IMOVANE exactly as you were told to, you are at risk for abuse, misuse, addiction, physical dependence and withdrawal. Abuse and misuse can result in overdose or death, especially if you take IMOVANE with:

- opioids
- alcohol or
- illicit drugs

Your healthcare professional should:

- talk to you about the risks of treatment with IMOVANE as well as other treatment (including non-drug) options
- assess your risk for these behaviours before prescribing IMOVANE
- monitor you while you are taking IMOVANE for the signs and symptoms of misuse and abuse. If you feel like you are craving IMOVANE, or not using it as directed, talk to your healthcare professional right away.

Store IMOVANE in a secure place to avoid theft or misuse.

Withdrawal: If you suddenly stop taking IMOVANE, lower your dose too fast, or switch to another medication, you can experience severe or life-threatening withdrawal symptoms (see Other warnings you should know about)

- Always contact your doctor before stopping, or lowering your dose of IMOVANE or changing your medicine.

IMOVANE with Opioids: Taking IMOVANE with opioid medicines can cause:

- severe drowsiness
- decreased awareness
- breathing problems
- coma
- death

Complex Sleep Behaviours:

Taking IMOVANE can cause complex sleep behaviours. This includes sleepwalking, sleep-driving and doing other activities while you are not fully awake. These behaviours can cause serious injuries, including death. Stop taking IMOVANE right away if you experience any complex sleep behaviours.
What is IMOVANE used for?

- IMOVANE is used in adults (over 18 years of age) for short term (usually not more than 7-10 days) insomnia. This is a sleep disorder that makes it hard to fall asleep, hard to stay asleep, or causes you to wake up too early. IMOVANE should only be used when the effects of insomnia affect your daytime activities.

- If you are 65 years or older, talk to your healthcare professional before starting IMOVANE. IMOVANE may not be an effective treatment for you and you may be more sensitive to experiencing side effects.

How does IMOVANE work?

IMOVANE works by increasing the activity of a chemical in your brain called gamma-aminobutyric-acid (GABA). This calms the brain which helps you go to sleep.

What are the ingredients in IMOVANE?

Medicinal ingredients: zopiclone

Non-medicinal ingredients:

5 mg: corn starch, dicalcium phosphate, hydroxypropyl-methylcellulose, lactose, magnesium stearate, sodium carboxymethyl starch and titanium dioxide.

7.5 mg: calcium phosphate dihydrate dibasic, carnauba wax, croscarmellose sodium, FD&C Blue #1, magnesium stearate, microcrystalline cellulose, Opadry II White and polyethylene glycol.

IMOVANE comes in the following dosage forms:

Tablet: 5 mg, 7.5 mg.

Do not use IMOVANE if:

- you are allergic to zopiclone or to any of the ingredients in IMOVANE
- you have a muscular disease known as myasthenia gravis (muscle weakness)
- you have severe liver problems
- you have severe lung or breathing problems such as sleep apnea (sleep disorder which causes pauses in breathing or shallow breathing while sleeping)
- you have a past history of unexpected reactions to other sedative medications. This can include driving, eating, making a phone call or having sex while not being fully awake.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take IMOVANE. Talk about any health conditions or problems you may have, including if you:

- have ever had a problem with:
  - substance use, including prescribed or illegal drugs (such as opioids), or
  - alcohol
- have ever had seizures or convulsions (violent uncontrollable shaking of the body with or without loss of consciousness)
- drink or plan to drink alcohol. Do not drink alcohol while you take IMOVANE.
• are taking other medications, including central nervous system (CNS) depressants (slow down brain activity)
• have a history or family history of sleepwalking
• have disorders that affect sleep such as Periodic Limb Movement (involuntary movement of limbs during sleep) or Restless Leg Syndrome (urge to move legs, typically in the evening and night)
• have liver or kidney problems
• are lactose intolerant or have one of the following diseases:
  ▪ Galactosemia
  ▪ Glucose-galactose malabsorption
• have a history of violent behaviour
• have had an unexpected reaction to sedative medications in the past, including alcohol and benzodiazepines
• have signs of depression or a history of depression
• have or have a history of suicidal thoughts or attempts or mental health problems
• have lung or breathing problems
• are 65 years of age or older
• are planning to become pregnant, if you are pregnant, or if you become pregnant while taking this medication
• are breastfeeding

Other warnings you should know about:

Complex Sleep Behaviours: IMOVANE can cause dangerous sleeping-related behaviours such as getting out of bed while not fully awake and doing activities that you do not know you are doing. You may not remember doing these activities when you wake up. These unusual behaviours may occur whether or not you drink alcohol or take other medicines that can make you sleepy, such as medicines used to treat depression or anxiety. The activities you may do in these situations can put you and people around you in danger. This can include driving a car (“sleep-driving”), leaving the house, making and eating food, having sex and talking on the phone. These behaviours can cause serious injuries, including death.

You and people close to you should watch out for unusual types of behavior when you are asleep. If you find out that you have done any such activities for which you have no memory, you should stop taking IMOVANE and call your healthcare professional right away.

Driving and Using Machines: IMOVANE may make you feel dizzy, drowsy and affect your coordination. DO NOT drive, use machinery, or do activities that require you to be alert:
• if it has not been 12 hours or more since you took IMOVANE, especially if you are elderly or you take the 7.5 mg dose.
• if you do not feel fully awake
• until you know how IMOVANE affects you
• if you are also taking opioid medicine
• if you have consumed alcohol
• if you are taking other medications, including central nervous system (CNS) depressants (slow down brain activity)
**Memory Problems:** IMOVANE can cause a type of memory loss known as amnesia. This is characterized by having trouble remembering events that recently occurred, usually several hours after taking the medication. This is not usually a problem if you take IMOVANE before sleeping. However, if you take IMOVANE to help sleep while travelling, such as during an airplane flight, you may wake up to memory lapse caused by the drug. This has been called “traveller’s amnesia” and can be a problem. DO NOT take IMOVANE when a full night’s sleep is not possible before you need to be active and functional (e.g., an overnight flight of less than 8 hours). Your body needs time to eliminate IMOVANE from your system.

**Dependence:** Taking IMOVANE can lead to physical dependence. The risk of dependence is greater when IMOVANE is used for longer than 4 weeks and in patients with a history of mental health problems and/or alcohol or drug abuse.

**Withdrawal:** If you suddenly stop your treatment, lower your dose too fast, or switch to another medication, you can experience withdrawal symptoms that can range from mild symptoms to severe or life threatening.

Your risk of going through withdrawal is higher if you are taking IMOVANE for a long time or at high doses. However, symptoms can still occur if you are taking IMOVANE as directed for a short period of time or slowly reducing the dose.

The symptoms of withdrawal often resemble the condition that you are being treated for. After stopping your treatment, it may be hard to tell if you are experiencing withdrawal or a return of your condition (relapse).

Tell your healthcare professional right away if you experience any symptoms of withdrawal after changing or stopping your treatment.

Severe symptoms of withdrawal include:
- a sudden and severe change in mental state that can cause a combination of confusion, disorientation and/or attention deficit (delirium)
- experiences of unreality or detachment from one’s surroundings (derealisation) and experiences of unreality or detachment from one’s mind, self, or body (depersonalisation)
- seeing or hearing things that are not there (hallucinations)
- sensitivity to sounds and noise (hyperacusis)
- convulsions (seizures), including some that do not stop

For other symptoms of withdrawal, see the **Serious side effects and what to do about them** table (below).

To reduce your chances of going through withdrawal:
- always contact your doctor before stopping or reducing your dose of IMOVANE or changing medications
- always follow your doctor’s instructions on how to reduce your dose carefully and safely
- tell your doctor right away if you experience any unusual symptoms after changing or stopping your treatment
**Falls and Fractures:**
Benzodiazepines or other sedative-hypnotic drugs, such as IMOVANE, can cause you to feel sleepy, dizzy and affect your balance. This increases your risks of falling, which can cause fractures or other fall related-injuries, especially if you:

- take other sedatives
- consume alcohol
- are elderly or
- have a condition that causes weakness or frailty

**Mental and Behavioural Changes:** A variety of abnormal thinking and behaviour changes may occur when you take IMOVANE. Some of these changes include aggressiveness and extroversion that seem out of character, delirium (a sudden and severe change in mental state which includes a combination of confused thinking, disorientation and decreased attention), confusion, strange behaviour, anxiety, restlessness, hallucinations, feeling like you are not yourself, worsening insomnia or depression, which may lead to suicidal thinking. If you develop any unusual thoughts or behaviour while using IMOVANE, tell your healthcare professional right away.

**Self-harm or Suicide:** If you have thoughts of harming or killing yourself at any time, contact your healthcare professional or go to a hospital **right away**. You may find it helpful to tell a relative or close friend that you are depressed or have other mental illnesses. Ask them to read this leaflet. You might ask them to tell you if they:

- think your depression or mental illness is getting worse, or
- are worried about changes in your behaviour

**Pregnancy:** Do not take IMOVANE if you are pregnant. IMOVANE may harm your unborn baby (e.g., birth defects) if you are pregnant. This risk is higher during the first trimester or last weeks of pregnancy. It may also cause side effects and withdrawal symptoms in your baby after birth. If you are able to get pregnant, want to be or think you are pregnant, there are specific risks you should discuss with your healthcare professional.

**Breastfeeding:** IMOVANE passes into breast milk. Do not breastfeed while taking IMOVANE. Talk to your healthcare professional about the best way to feed your baby while you are taking IMOVANE.

**Blood Tests:** IMOVANE can cause abnormal blood test results. Your healthcare professional will decide when to perform blood tests and will interpret the results.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with IMOVANE:**

<table>
<thead>
<tr>
<th>Serious Drug Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking IMOVANE and opioids may cause:</td>
</tr>
<tr>
<td>- severe drowsiness</td>
</tr>
<tr>
<td>- trouble breathing</td>
</tr>
<tr>
<td>- coma</td>
</tr>
<tr>
<td>- death</td>
</tr>
</tbody>
</table>

Tell your healthcare professional if you:
• are taking opioid medicines
• are prescribed an opioid medicine after you start taking IMOVANE

- alcohol. Do not take IMOVANE if you drink alcohol
- other hypnotics or sedatives that are used to help with sleeping
- sedative antihistamines that are used to treat allergies
- anticonvulsants used to prevent or treat seizures
- anesthetics, used during surgery
- medicines used to treat mental health disorders (antipsychotics and psychotropic medication)
- medicines used to treat fungal and bacterial infections such as ketoconazole, itraconazole, rifampicin, rifampin, erythromycin and clarithromycin
- ritonavir, used to treat HIV
- medicines used to treat or prevent seizures such as carbamazepine, phenytoin and phenobarbital
- St John’s wort, an herbal medicine

How to take IMOVANE:

• Always take IMOVANE exactly as your healthcare professional tells you to. Do not change your dose without talking to your healthcare professional.
• Take IMOVANE by mouth just before going to bed. Do not take IMOVANE if a full night’s sleep is not possible before you need to become active and functional again.
• Do not consume any alcohol while taking IMOVANE.

Remember: This medication is for YOU. Never give it to others. It may harm them even if their symptoms are the same as yours.

Usual dose:

• The usual adult starting dose is 3.75 mg. This is one half of the 7.5 mg tablet.
• Based on your response and tolerability of IMOVANE, your age, other medical conditions you have and other medicines you are taking, your healthcare professional may change your dose. Your healthcare professional will ensure the lowest effective dose is prescribed.

Your healthcare professional will slowly decrease your dose and will tell you when to stop taking the medicine. Always follow your doctor’s instructions on how to lower your dose carefully and safely to avoid experiencing withdrawal symptoms.

Overdose:

If you think you, or a person you are caring for, have taken too much IMOVANE, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you missed a dose of this medication, you do not need to make up the missed dose. Skip the missed dose and continue with your next scheduled dose. Do not take two doses at the same time.

What are possible side effects from using IMOVANE?
These are not all the possible side effects you may have when taking IMOVANE. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- bitter taste, dry mouth, bad breath
- drowsiness
- dizziness or light-headedness
- difficulty with coordination
- decreased muscle tone
- nausea or vomiting
- anorexia or increased appetite
- constipation or diarrhea
- abnormal weakness or lack of energy
- muscle weakness
- rashes, spots on your skin, or itchy skin
- seeing double
- palpitations
- falls and fractures

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom / effect</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>UNCOMMON</strong></td>
</tr>
<tr>
<td>Mental and behavioural changes:</td>
</tr>
<tr>
<td>excitement, agitation, hyperactivity, delirium,</td>
</tr>
<tr>
<td>hallucination, worsened insomnia,</td>
</tr>
<tr>
<td>aggression, irritability, rages, psychoses,</td>
</tr>
<tr>
<td>and violent behaviour symptom</td>
</tr>
<tr>
<td><strong>Severe allergic reactions:</strong></td>
</tr>
<tr>
<td>swelling of the tongue or throat, trouble</td>
</tr>
<tr>
<td>breathing, sudden wheeziness, chest pain or</td>
</tr>
<tr>
<td>tightness, shortness of breath, throat closing,</td>
</tr>
<tr>
<td>nausea, or vomiting. Other allergic reactions</td>
</tr>
<tr>
<td>may include rashes, spots on your skin, or</td>
</tr>
<tr>
<td>itchy skin</td>
</tr>
<tr>
<td><strong>RARE</strong></td>
</tr>
<tr>
<td>Amnesia (a type of memory loss):</td>
</tr>
<tr>
<td>difficulty recalling events that recently</td>
</tr>
<tr>
<td>happened</td>
</tr>
<tr>
<td><strong>Complex sleep behaviours:</strong></td>
</tr>
<tr>
<td>getting out of bed while not fully</td>
</tr>
<tr>
<td>Symptom / effect</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>awake and doing activities you do not remember the day after, including sleep walking, driving, making phone calls, or having sex</td>
</tr>
<tr>
<td>UNKNOWN</td>
</tr>
<tr>
<td><strong>Overdose:</strong> extreme sleepiness, confusion, slurred speech, slow reflexes, slow shallow breathing, coma, loss of balance and coordination, uncontrolled rolling of the eyes, and low blood pressure.</td>
</tr>
<tr>
<td><strong>Respiratory Depression:</strong> slow, shallow or weak breathing.</td>
</tr>
<tr>
<td><strong>Self-harm or Suicide:</strong> thoughts or actions about hurting or killing yourself</td>
</tr>
<tr>
<td><strong>Withdrawal:</strong> Severe symptoms include:</td>
</tr>
<tr>
<td><strong>Delirium:</strong> sudden and severe change in mental state that can cause a combination of confusion, disorientation and/or attention deficit</td>
</tr>
<tr>
<td><strong>Derealization:</strong> experiences of unreality or detachment from one’s surroundings</td>
</tr>
<tr>
<td><strong>Depersonalization:</strong> experiences of unreality or detachment from one’s mind, self, or body</td>
</tr>
<tr>
<td><strong>Hallucinations:</strong> seeing or hearing things that are not there</td>
</tr>
<tr>
<td><strong>Hyperacusis:</strong> sensitivity to sounds and noise</td>
</tr>
<tr>
<td><strong>Convulsions:</strong> (seizures – including some that do not stop): loss of consciousness with uncontrollable shaking</td>
</tr>
<tr>
<td><strong>Other symptoms include:</strong> Stomach cramps; trouble remembering or concentrating;</td>
</tr>
<tr>
<td>diarrhea; feeling uneasy or</td>
</tr>
</tbody>
</table>
Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>restless; severe anxiety; headache; sensitivity to light, noise or physical contact; shaking; vomiting; trouble sleeping; feeling irritable; muscle pain or stiffness; a burning or prickling feeling in the hands, arms, legs or feet; sweating.</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

**Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting ([https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html)) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

**Storage:**

Store in a dry place, at room temperature (15°C - 30°C). Protect from light. Do not exceed the expiry date indicated on the container.

Keep in a safe place out of reach and sight of children.

**If you want more information about IMOVANE:**

- Talk to your healthcare professional

This leaflet was prepared by sanofi-aventis Canada Inc.

Last Revised April 6, 2022